Arcus Biosciences Inc (RCUS)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 150,000 | 201,000 | 156,000 | 185,000 | 127,000 | 184,000 | 230,000 | 238,000 | 206,000 | 218,000 | 273,000 | 549,000 | 148,000 | 179,432 | 320,482 | 390,260 | 173,415 | 221,849 | 285,185 | 67,326 |
| Short-term investments | US$ in thousands | 828,000 | 888,000 | 813,000 | 810,000 | 632,000 | 615,000 | 700,000 | 716,000 | 803,000 | 831,135 | 900,147 | 664,751 | 351,394 | 345,210 | 400,530 | 436,666 | 555,231 | 560,583 | 177,288 | 90,540 |
| Total current liabilities | US$ in thousands | 226,000 | 215,000 | 199,000 | 204,000 | 184,000 | 200,000 | 180,000 | 179,000 | 193,000 | 177,176 | 164,024 | 161,254 | 166,000 | 142,866 | 130,370 | 132,055 | 121,669 | 162,871 | 40,025 | 21,004 |
| Cash ratio | 4.33 | 5.07 | 4.87 | 4.88 | 4.12 | 4.00 | 5.17 | 5.33 | 5.23 | 5.92 | 7.15 | 7.53 | 3.01 | 3.67 | 5.53 | 6.26 | 5.99 | 4.80 | 11.55 | 7.52 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($150,000K
+ $828,000K)
÷ $226,000K
= 4.33
The cash ratio of Arcus Biosciences Inc has shown some fluctuations over the past few years, ranging from a low of 3.01 on December 31, 2021, to a high of 11.55 on June 30, 2020. The cash ratio measures the company's ability to cover its current liabilities with its cash and cash equivalents. Generally, a higher cash ratio indicates a stronger liquidity position and suggests that the company is better equipped to meet its short-term obligations.
In the most recent period of December 31, 2024, the cash ratio stands at 4.33, indicating that the company has $4.33 in cash and cash equivalents for every $1 of its current liabilities. This suggests that Arcus Biosciences Inc has a reasonable level of liquidity to meet its short-term financial obligations. However, a decreasing trend in the cash ratio over time may signal potential issues with liquidity management or a decrease in the company's cash reserves relative to its current liabilities.
It is important for investors and stakeholders to continue monitoring Arcus Biosciences Inc's cash ratio over time to assess the company's liquidity position and its ability to navigate potential financial challenges in the future.
Peer comparison
Dec 31, 2024